DE602004027409D1 - Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation - Google Patents
Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregationInfo
- Publication number
- DE602004027409D1 DE602004027409D1 DE602004027409T DE602004027409T DE602004027409D1 DE 602004027409 D1 DE602004027409 D1 DE 602004027409D1 DE 602004027409 T DE602004027409 T DE 602004027409T DE 602004027409 T DE602004027409 T DE 602004027409T DE 602004027409 D1 DE602004027409 D1 DE 602004027409D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- aggregation
- trombozyte
- dedioxol
- tetrahydrofuro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 238000004220 aggregation Methods 0.000 title 1
- 230000002776 aggregation Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 2
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- -1 nucleotide compound Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51384503P | 2003-10-21 | 2003-10-21 | |
| PCT/US2004/035389 WO2005040174A1 (en) | 2003-10-21 | 2004-10-21 | Tetrahydro-furo`3,4-d!dioxole compounds and compositions and method for inhibiting platelet aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004027409D1 true DE602004027409D1 (de) | 2010-07-08 |
Family
ID=34520144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004027409T Expired - Lifetime DE602004027409D1 (de) | 2003-10-21 | 2004-10-21 | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7368438B2 (de) |
| EP (1) | EP1685135B1 (de) |
| JP (1) | JP2007514647A (de) |
| AT (1) | ATE469157T1 (de) |
| AU (2) | AU2004284098B2 (de) |
| DE (1) | DE602004027409D1 (de) |
| WO (1) | WO2005040174A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7452870B2 (en) | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
| US7749981B2 (en) * | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
| JP2007509180A (ja) * | 2003-10-21 | 2007-04-12 | インスパイアー ファーマシューティカルズ，インコーポレイティド | 疼痛を治療するための、非ヌクレオチド組成物および方法 |
| US7504497B2 (en) * | 2003-10-21 | 2009-03-17 | Inspire Pharmaceuticals, Inc. | Orally bioavailable compounds and methods for inhibiting platelet aggregation |
| US7335648B2 (en) * | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| US7741473B2 (en) * | 2005-03-30 | 2010-06-22 | Inspire Pharmaceuticals, Inc. | Process for the preparation of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles |
| EP1943261A2 (de) * | 2005-11-04 | 2008-07-16 | Inspire Pharmaceuticals, Inc. | Mit einer nichtnukleotidischen, p2y12-rezeptor-antagonistischen verbindung beschichtete arzneimittel eluierende stents |
| US20070249556A1 (en) * | 2006-04-21 | 2007-10-25 | Brubaker Kurt E | Method of treating inflammation |
| CN101479290A (zh) * | 2006-06-27 | 2009-07-08 | 比奥维特罗姆上市公司 | 新的2′,3′-亚甲基缩醛腺苷前药用作腺苷受体激动剂的前药 |
| AU2008259965B2 (en) * | 2007-05-30 | 2011-07-07 | Brigham Young University | Protein kinase-binding nucleosides and associated methods |
| CA2747188C (en) * | 2008-11-20 | 2017-06-13 | Glsynthesis Inc. | Antithrombotic diadenosine tetraphosphates and related analogs |
| CA2747658A1 (en) * | 2008-12-18 | 2010-07-15 | Inspire Pharmaceuticals, Inc. | Method for treating inflammatory conditions |
| EP2408306A4 (de) * | 2009-03-20 | 2012-11-07 | Alios Biopharma Inc | Substituierte nukleosid- und nukleotid-analoga |
| BR112013005872A2 (pt) | 2010-09-22 | 2019-09-24 | Alios Biopharma Inc | compostos, composição farmacêutica e respectivos usos |
| JP5768422B2 (ja) * | 2011-03-17 | 2015-08-26 | ソニー株式会社 | 血液凝固系解析方法および血液凝固系解析装置 |
| EP2750676B1 (de) | 2011-08-30 | 2018-01-10 | University of Utah Research Foundation | Verfahren und zusammensetzungen zur behandlung von nephrogenem diabetes insipidus |
| CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
| US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
| HK1203356A1 (en) | 2012-03-22 | 2015-10-30 | 艾丽奥斯生物制药有限公司 | Pharmaceutical combinations comprising a thionucleotide analog |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3321462A (en) * | 1963-07-15 | 1967-05-23 | Syntex Corp | Process for the preparation of nucleoside polyphosphates |
| AU8379182A (en) | 1981-06-04 | 1982-12-09 | Procter & Gamble Company, The | Composition of salicylates and purine derivatives |
| US4794174A (en) * | 1987-02-10 | 1988-12-27 | Southern Research Institute | 5'deoxy-5'-substituted adenosines |
| US5049550A (en) * | 1987-11-05 | 1991-09-17 | Worcester Foundation For Experimental Biology | Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents |
| US5292725A (en) * | 1988-08-25 | 1994-03-08 | Prendergast Patrick T | Administering particular compounds against various parasites, mycoplasmas, other indications and other infections |
| NZ239846A (en) * | 1990-09-27 | 1994-11-25 | Merck & Co Inc | Sulphonamide derivatives and pharmaceutical compositions thereof |
| GB9122308D0 (en) * | 1991-10-21 | 1991-12-04 | British Bio Technology | Compounds |
| WO1996019223A1 (en) * | 1994-12-22 | 1996-06-27 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
| SK283206B6 (sk) * | 1995-07-11 | 2003-03-04 | Astra Pharmaceuticals Ltd. | Inhibítory agregácie krvných doštičiek, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie |
| US5681823A (en) * | 1996-05-02 | 1997-10-28 | Prp Inc. | P1, P4 -dithio-P2 -P3 -monochloromethylene 5', 5'"-diadenosine P1, P4 -tetraphosphate as antithrombotic agent |
| AU5501598A (en) | 1996-12-20 | 1998-07-17 | Astra Pharmaceuticals Limited | Triazolo{4,5-(d)}pyrimidinyl derivatives and their use as medicaments |
| SE9702774D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| TW530058B (en) | 1997-07-22 | 2003-05-01 | Astra Pharma Prod | Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation |
| SE9702772D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| EP1019427A4 (de) * | 1997-07-29 | 2000-07-19 | Medco Res Inc | N6-substituierte adenosin-5'-uronamide als adenosin-rezeptor-modulatoren |
| CA2316264A1 (en) * | 1998-02-17 | 1999-08-19 | Brian Springthorpe | Novel triazolo(4,5-d)pyrimidine compounds |
| SE9802574D0 (sv) | 1998-07-17 | 1998-07-17 | Astra Pharma Prod | Novel compounds |
| SE9804175D0 (sv) * | 1998-12-02 | 1998-12-02 | Astra Pharma Prod | New assay |
| SE9903290D0 (sv) * | 1999-09-15 | 1999-09-15 | Astra Pharma Prod | Novel compounds |
| SE9904128D0 (sv) * | 1999-11-15 | 1999-11-15 | Astra Pharma Prod | Novel compounds |
| US6605597B1 (en) | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| TWI227240B (en) | 2000-06-06 | 2005-02-01 | Pfizer | 2-aminocarbonyl-9H-purine derivatives |
| US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| SE0101932D0 (sv) | 2001-05-31 | 2001-05-31 | Astrazeneca Ab | Pharmaceutical combinations |
| EP1348466A3 (de) | 2002-02-01 | 2003-10-29 | Inspire Pharmaceuticals, Inc. | Schmerzbehandlung mit Adenosin-Tetraphosphaten |
| ES2348942T3 (es) * | 2002-12-11 | 2010-12-17 | Bayer Schering Pharma Aktiengesellschaft | Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor plaquetario de adenosin difosfato. |
| US7335648B2 (en) * | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
-
2004
- 2004-10-21 WO PCT/US2004/035389 patent/WO2005040174A1/en not_active Ceased
- 2004-10-21 JP JP2006536918A patent/JP2007514647A/ja not_active Withdrawn
- 2004-10-21 AU AU2004284098A patent/AU2004284098B2/en not_active Ceased
- 2004-10-21 AT AT04796377T patent/ATE469157T1/de not_active IP Right Cessation
- 2004-10-21 EP EP04796377A patent/EP1685135B1/de not_active Expired - Lifetime
- 2004-10-21 US US10/971,766 patent/US7368438B2/en not_active Expired - Fee Related
- 2004-10-21 DE DE602004027409T patent/DE602004027409D1/de not_active Expired - Lifetime
-
2009
- 2009-10-06 AU AU2009222625A patent/AU2009222625A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050159388A1 (en) | 2005-07-21 |
| JP2007514647A (ja) | 2007-06-07 |
| WO2005040174A1 (en) | 2005-05-06 |
| US7368438B2 (en) | 2008-05-06 |
| ATE469157T1 (de) | 2010-06-15 |
| AU2009222625A1 (en) | 2009-10-29 |
| AU2004284098B2 (en) | 2009-07-16 |
| AU2004284098A1 (en) | 2005-05-06 |
| EP1685135A1 (de) | 2006-08-02 |
| EP1685135B1 (de) | 2010-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004027409D1 (de) | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation | |
| WO2006119507A3 (en) | Non-nucleotide composition and method for inhibiting platelet aggregation | |
| TWI265931B (en) | Composition and method for inhibiting platelet aggregation | |
| EA200300424A1 (ru) | Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов | |
| ATE517882T1 (de) | Chinolinderivate | |
| ATE464304T1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonist n | |
| EA200702339A1 (ru) | Замещенные амидные производные в качестве ингибиторов протеинкиназы | |
| DE60324544D1 (de) | Muskarin antagonisten | |
| EA200500814A1 (ru) | Производные пирролопиримидина | |
| EA200901159A1 (ru) | Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она | |
| ATE446303T1 (de) | Agonisten und antagonisten von sphingosin-1- phosphatrezeptoren | |
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| AR036596A1 (es) | Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1 | |
| EA201101398A1 (ru) | Замещенные пиперидины в качестве антагонистов ccr3 | |
| PL1716152T3 (pl) | Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych | |
| SE0302760D0 (sv) | New compounds | |
| BR0309486A (pt) | Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas | |
| TW200719886A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| BR9909597A (pt) | Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas | |
| TW200728260A (en) | Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof | |
| EA200400467A1 (ru) | Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора | |
| ATE372995T1 (de) | Benzo(b)(1,4)dioxepinderivate | |
| DE602005027230D1 (de) | Cgrp-rezeptorantagonisten | |
| EA200500899A1 (ru) | Антагонисты аденозиндифосфатного рецептора тромбоцитов | |
| EA200901474A1 (ru) | Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |